Scores of amino acid 0D-3D information as applied in cleavage site prediction and better specificity elucidation for human immunodeficiency virus type 1 protease

被引:3
|
作者
Kang LiFang [1 ]
Liang GuiZhao [1 ]
Shu Mao [1 ]
Yang ShanBin [1 ,2 ]
Li ZhiLiang [1 ,2 ]
机构
[1] Chongqing Univ, Coll Bioengn, Chongqing 400030, Peoples R China
[2] Chongqing Univ, Coll Chem & Chem Engn, Chongqing 400030, Peoples R China
来源
SCIENCE IN CHINA SERIES B-CHEMISTRY | 2008年 / 51卷 / 08期
关键词
score vector of zero dimension; one dimension; two dimensions and three dimensions (SZOTT); human immunodeficiency virus type 1 protease (HIV PR); linear discriminant analysis (LDA); support vector machine (SVM);
D O I
10.1007/s11426-008-0088-2
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
A new set of descriptors, namely score vectors of the zero dimension, one dimension, two dimensions and three dimensions (SZOTT), was derived from principle component analysis of a matrix of 1369 structural variables including 0D, 1D, 2D and 3D information for the 20 coded amino acids. SZOTT scales were then used in cleavage site prediction of human immunodeficiency virus type 1 protease. Linear discriminant analysis (LDA) and support vector machines (SVM) were applied to developing models to predict the cleavage sites. The results obtained by linear discriminant analysis (LDA) and support vector machines (SVM) are as follows. The Matthews correlation coefficients (MCC) by the resubstitution test, leave-one-out cross validation (LOOCV) and external validation are 0.879 and 0.911, 0.849 and 0.901, 0.822 and 0.846, respectively. The receiver operating characteristic (ROC) analysis showed that the SVM model possesses better simulative and predictive ability in comparison with the LDA model. Satisfactory results show that SZOTT descriptors can be further used to predict cleavage sites of human immunodeficiency virus type 1 protease.
引用
收藏
页码:794 / 800
页数:7
相关论文
共 50 条
  • [31] Inhibitors of human immunodeficiency virus type 1 protease containing 2-aminobenzyl-substituted 4-amino-3-hydroxy-5-phenylpentanoic acid: Synthesis, activity, and oral bioavailability
    Lehr, P
    Billich, A
    Charpiot, B
    Ettmayer, P
    Scholz, D
    Rosenwirth, B
    Gstach, H
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (10) : 2060 - 2067
  • [32] The D1-A2 and D2-A2 pairs of splice sites from human immunodeficiency virus type 1 are highly efficient in vitro, in spite of an unusual branch site
    Damier, L
    Domenjoud, L
    Branlant, C
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 237 (01) : 182 - 187
  • [33] Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and virion encapsidation
    Huthoff, Hendrik
    Malim, Michael H.
    [J]. JOURNAL OF VIROLOGY, 2007, 81 (08) : 3807 - 3815
  • [34] Human immunodeficiency virus type 1 reverse-transcriptase and protease subtypes: Classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population
    Gonzales, MJ
    Machekano, RN
    Shafer, RW
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2001, 184 (08): : 998 - 1006
  • [35] Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1
    Sugiura, W
    Matsuda, Z
    Yokomaku, Y
    Hertogs, K
    Larder, B
    Oishi, T
    Kano, A
    Shiino, T
    Tatsumi, M
    Matsuda, M
    Abumi, H
    Takata, N
    Shirahata, S
    Yamada, K
    Yoshikura, H
    Nagai, Y
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) : 708 - 715
  • [36] Structural prerequisites for intersubtype B and D antigenicity of the third variable envelope region (V3) of human immunodeficiency virus type 1
    Lawoko, A
    Johansson, B
    Ljunggren, J
    Fries, A
    Fredriksson, R
    Georgievska, L
    Malmvall, B
    Pipkorn, R
    Fenyö, EM
    Blomberg, J
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2000, 182 (01): : 49 - 58
  • [37] The role of lysine residue at amino acid position 165 of human immunodeficiency virus type 1 CRF01_AE Gag in reducing viral drug susceptibility to protease inhibitors
    Kameoka, Masanori
    Isarangkura-na-ayuthaya, Panasda
    Kameoka, Yoko
    Sapsutthipas, Sompong
    Soonthornsata, Bongkot
    Nakamura, Shota
    Tokunaga, Kenzo
    Sawanpanyalert, Pathom
    Ikuta, Kazuyoshi
    Auwanit, Wattana
    [J]. VIROLOGY, 2010, 405 (01) : 129 - 138
  • [38] 3D-QSAR, molecular docking, and molecular dynamics simulation of a novel thieno[3,4-d]pyrimidine inhibitor targeting human immunodeficiency virus type 1 reverse transcriptase
    Chu, Han
    He, Qing-xiu
    Wang, Jun-wei
    Deng, Ya-ting
    Wang, Juan
    Hu, Yong
    Wang, Yuan-qiang
    Lin, Zhi-hua
    [J]. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2020, 38 (15): : 4567 - 4578
  • [39] Human immunodeficiency virus type 1 Tat protein directly activates neuronal N-methyl-D-aspartate receptors at an allosteric zinc-sensitive site
    Song, L
    Nath, A
    Geiger, JD
    Moore, A
    Hochman, S
    [J]. JOURNAL OF NEUROVIROLOGY, 2003, 9 (03) : 399 - 403
  • [40] Human immunodeficiency virus type 1 Tat protein directly activates neuronal N-methyl-d-aspartate receptors at an allosteric zinc-sensitive site
    L. Song
    A. Nath
    J. D. Geiger
    A. Moore
    S. Hochman
    [J]. Journal of NeuroVirology, 2003, 9 : 399 - 403